William Blair & Company’s Heron Therapeutics HRTX Stock Holding History

William Blair & Company’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,500	Closed	-$78K	–	1845
2022 Q3	$78K	Hold	18,500	–	–	﹤0.01%	1538
2022 Q2	$52K	Hold	18,500	–	–	﹤0.01%	1625
2022 Q1	$106K	Hold	18,500	–	–	﹤0.01%	1629
2021 Q4	$169K	Hold	18,500	–	–	﹤0.01%	1614
2021 Q3	$198K	Hold	18,500	–	–	﹤0.01%	1510
2021 Q2	$287K	Hold	18,500	–	–	﹤0.01%	1358
2021 Q1	$300K	Hold	18,500	–	–	﹤0.01%	1331
2020 Q4	$392K	Hold	18,500	–	–	﹤0.01%	1161
2020 Q3	$274K	Hold	18,500	–	–	﹤0.01%	1174
2020 Q2	$272K	Buy	+18,500	New	+$304K	﹤0.01%	1137

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

William Blair & Company's HRTX Position: Q4 2022 in Review

William Blair & Company sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 18,500 shares — an estimated $78K sold.

William Blair & Company first reported a position in HRTX in Q2 2020 and held it in 10 quarters. The position peaked at $392K in Q4 2020. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

William Blair & Company reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
William Blair & Company sold 18,500 Heron Therapeutics shares in Q4 2022, an estimated $78K.
William Blair & Company first reported a position in Heron Therapeutics in Q2 2020 and held it in 10 quarters.
William Blair & Company's Heron Therapeutics position peaked at $392K in Q4 2020.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on William Blair & Company's 13F filing for Q4 2022, filed 10 Feb 2023.